|
Middleton M.R.
|
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potentially Activated Antitumour Immune Responses in Patients with Metastatic Melanoma |
2020-08 |
View
|
|
Fergusson J.R.
|
Epub ahead of print: Immune-mobilising monoclonal T cell receptors mediate specific and rapid elimination of Hepatitis B-infected cells |
|
View
|
|
Coles C.H., Mulvaney R.M.
|
T cell receptors with distinct specificity profiles use different binding modes to engage an identical peptide-HLA complex. J Immunol. 2020 Apr 1;204(7):1943-1953. |
2020-02 |
View
|
|
Damato B.E.
|
Tebentafusp: T Cell Redirection for the Treatment of Advanced Uveal Melanoma. Cancers 2019 Jul 11;11(7). pii: E971. |
2019-07 |
View
|
|
Madura F.
|
TCR-induced alteration of primary MHC peptide anchor residue. Eur. J. Immunol. 2019 Jul;49(7):1052-1066. |
2019-05 |
View
|
|
Lowe K.L.
|
Novel TCR-based biologics: mobilising T cells to warm ‘cold’ tumours. Cancer Treat Rev. 2019 Jul;77:35-43. |
|
View
|
|
Dobrzycki T., Ciuntu A.
|
Assessing the potency of T cell redirecting therapeutics using in vitro cancer cell killing assays. Immuno-Oncology: Cellular and Translational Approaches, Springer Methods. 2019 |
2019-01 |
|
|
Sato T, et al.
|
Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T cell based toxicity and preliminary efficacy in advanced uveal melanoma (2017) ASCO. |
2017-05 |
News article
|
|
Carvajal, R, et al.
|
Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector, IMCgp100 in advanced uveal melanoma in two Phase 1 trials (2017) SITC. |
|
News article
|
|
Boudousquie C. et al.
|
Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells (2017) Immunology. 152(3):425-438. |
|
PubMed
|
|
Middleton, R M.
|
Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific T cell redirector with solid tumour activity: Results from the FIH study in melanoma (2016) ASCO. |
2016-05 |
News article
|
|
Bossi G. et al.
|
ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. (2014) Cancer Immunol Immunother. 63(5):437-48. |
|
PubMed
|
|
Bossi G. et al.
|
Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells. (2013) Oncoimmunology. Nov 1;2(11):e26840. |
|
PubMed
|
|
Oates J. et al.
|
ImmTACs for targeted cancer therapy: Why, what, how, and which (2015) Mol Immunol. 67(2 Pt A):67-74. |
|
PubMed
|
|
McCormack E. et al.
|
Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. (2013) Cancer Immunol Immunother 62(4):773-85. |
|
PubMed
|
|
Oates J. and Jakobsen B.K.
|
ImmTACs: Novel bi-specific agents for targeted cancer therapy. (2013) Oncoimmunology 2(2):1-2. |
|
PubMed
|
|
Liddy N. et al.
|
Monoclonal TCR-redirected tumor cell killing. (2012) Nat Med 18(6):980-7. |
|
PubMed
|
|
Yang H. et al.
|
Elimination of latently HIV-infected cells from antiretroviral therapy-suppressed subjects by engineered immune mobilising T cell receptors. (2016) Molecular Therapy. 24(11):1913-1925. |
|
PubMed
|
|
Liddy N. et al.
|
Production of a soluble disulfide bond-linked TCR in the cytoplasm of Escherichia coli trxB gor mutants. (2010) Mol Biotechnol 45(2):140-9. |
|
PubMed
|
|
Dunn S.M. et al.
|
Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity. (2006) Protein Sci 15(4):710-21. |
|
PubMed
|
|
Li Y. et al.
|
Directed evolution of human T-cell receptors with picomolar affinities by phage display. (2005) Nat Biotechnol 23(3):349-54. |
|
PubMed
|
|
Ashfield R. and Jakobsen B.K.
|
Making high-affinity T-cell receptors: a new class of targeted therapeutics. (2006) IDrugs 9(8):554-9. |
|
PubMed
|
|
Boulter J.M. and Jakobsen B.K.
|
Stable, soluble, high-affinity, engineered T cell receptors: novel antibody-like proteins for specific targeting of peptide antigens. (2005) Clin Exp Immunol 142(3):454-60. |
2005-12 |
PubMed
|
|
Boulter J.M. et al.
|
Stable, soluble T-cell receptor molecules for crystallization and therapeutics. (2003) Protein Eng 16(9):707-11. |
2003-09 |
PubMed
|
|
Sami M. et al.
|
Crystal structures of high affinity human T-cell receptors bound to peptide major histocompatibility complex reveal native diagonal binding geometry. (2007) Protein Eng Des Sel 20(8):397-403. |
|
PubMed
|
|
Raman, M. C. et al.
|
Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy. (2016) Sci Rep 6. 18851. |
|
PubMed
|
|
Cameron B.J. et al.
|
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. (2013) Sci Trans Med Aug 7;5(197):197ra103. |
|
PubMed
|
|
Hickman, E. S. et al.
|
Antigen Selection for Enhanced Affinity T-Cell Receptor-Based Cancer Therapies. (2016) J Biomol Screen. 21(8):769-85. |
|
PubMed
|
|
Purbhoo M.A. et al.
|
Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. (2006) J Immunol 176(12):7308-16. |
|
PubMed
|
|
Lissin N. et al.
|
High-Affinity Monoclonal T-cell receptor (mTCR) Fusions. Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges. (2013). |
|
Wiley
|
|
Hassan N.J. and Oates J.
|
The T Cell Promise. (2013) European Biopharmaceutical Review (Summer 2013). |
2013-12 |
View
|
|
Aleksic M. et al.
|
Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. (2012) Eur J Immunol 42(12):3174-9. |
|
PubMed
|
|
Sato T, et al.
|
Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-direct TCR IMCgp100: Overall survival findings (2018) ASCO. |
|
News article
|
|
Patel M et al.
|
iS-CellR: a user-friendly tool for analyzing and visualizing single-cell RNA sequencing data (2018). Bioinformatics. |
|
PubMed
|
|
Harper J, et al.
|
An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules (2018). PLOS One. |
|
PubMed
|
|
Crean R., et al.
|
Reliable In Silico Ranking of Engineered Therapeutic TCR Binding Affinities with MMPB/GBSA. J Chem Inf Model 2022; 62(3): 577-590 |
2022-01 |
View
|
|
Weaver E., et al.
|
Microfluidic-mediated self-assembly of phospholipids for the delivery of biologic molecule. Int J Pharm 2022; 611: 121347 |
2022-01 |
View
|
|
Barber, C., et al.
|
Structure-guided stabilization of pathogen-derived peptide-HLA-E complexes using non-natural amino acids conserves native TCR recognition. Eur J Immunol 2022; 52(4): 618-632 |
2022-02 |
View
|
|
Carvajal, R. D., et al.
|
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. J Clin Oncol 2022; 40(17): 1939 |
2022-03 |
View
|
|
Hopkins J.R., et al.
|
Unconventional modes of peptide-HLA-I presentation change the rules of TCR engagement. Discov Immunol 2022; 1(1) kyac001 |
2022-05 |
View
|
|
Poole, A. et al.
|
Therapeutic high affinity T cell receptor targeting a KRAS<sup>G12D</sup> cancer neoantigen. Nat Comms 2022; 13(1): 5333 |
2022-09 |
View
|
|
Carvajal, R. D. et al.
|
Clinical and molecular response to tebentafusp in previously-treated patients with metastatic uveal melanoma: a phase 2 trial. Nat Med 2022; 28(11): 2364-2373 |
2022-10 |
View
|
|
Wallace Z. et al.
|
Combination strategies to durably suppress HIV-1: Soluble T cell receptors. J Virus Erad 2022; 8(3): 100082 |
2022-09 |
View
|
|
Wallace Z. et al.
|
Immune mobilising T cell receptors redirect polyclonal CD8+ T cells in chronic HIV infection to form immunological synapses. Sci Rep 2022; 12(1):18366 |
2022-11 |
View
|
|
Salio, M.
|
Unconventional MAIT cell responses to bacterial infections. Semin Immunol 2022; 61-64: 101663 |
2022-11 |
View
|
|
Weaver E., et al.
|
The manufacturing of 3D-printed microfluidic chips to analyse the effect upon particle size during the synthesis of lipid nanoparticles. J Pharm Pharmacol 2022; rgac085 |
2022-12 |
View
|
|
Berman DM, Bell JI.
|
Redirecting Polyclonal T Cells against Cancer with Soluble T-Cell Receptors. Clin Cancer Res. 2023;29(4):697-704 |
2023-02 |
View
|
|
Hamid, O. et al.
|
Tebentafusp in Combination with Durvalumab and/or Tremelimumab in Patients with Metastatic Cutaneous Melanoma: A Phase 1 Study. J Immunother Cancer. 2023 Jun;11(6):e006747. |
2023-06 |
View
|
|
Chancellor. A. et al.
|
Promiscuous recognition of MR1 drives self-reactive mucosal-associated invariant T cell responses. J Exp Med 4 September 2023; 220 (9): e20221939. |
2023-06 |
View
|
|
Knezevic. L. et al.
|
High-affinity CD8 variants enhance the sensitivity of pMHCI antigen recognition via low-affinity TCRs. J Biol Chem. 2023;299(8):104981. |
2023-08 |
View
|
|
Weaver, E., et al.
|
Microfluidic Encapsulation of Enzymes and Steroids within Solid Lipid Nanoparticles. Drug Deliv Transl Res. 2024;14(1):266-279. |
2023-07 |
View
|
|
Robertson, I.B. et al.
|
Tuning the potency and selectivity of ImmTAC molecules by affinity modulation. Clin Exp Immunol. 2024;215(2):105-119. |
2023-11 |
View
|
|
Hassel, J.C. & Piperno-Neumann, S. et al.
|
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2023;389(24):2256-2266. |
2023-10 |
View
|
|
Meyer, M. et al.
|
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics. Nat Rev Drug Discov. 2024;23(1):1-2 |
2023-11 |
View
|
|
Piulats, JM et al.
|
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis. Ann Oncol. 2024;35(3):317-326. |
2023-12 |
View
|
|
Wallace Z. et al.
|
Instability of the HLA-E peptidome of HIV presents a major barrier to therapeutic targeting. Mol Ther. 2024;32(3):678-688. |
2024-01 |
View
|
|
Paterson, R. et al.
|
An HLA-E-targeted TCR bispecific molecule redirects T cell immunity against Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2024;121(19):e2318003121. |
2024-05 |
View
|
|
Sacco JJ, Carvajal RD et al.
|
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma. J Immunother Cancer. 2024;12(6):e009028. |
2024-06 |
View
|
|
Coles, C.H. Mulvaney R.M. et al.
|
T cell receptors with distinct specificity profiles use different binding modes to engage an identical peptide-HLA complex. J. Immunol. 2020;204(7):1943-1953. |
2020-04 |
News article
|
|
Holland C.J. et al.
|
Specificity of bispecific TCRs and antibodies targeting peptide-HLA. J. Clin. Invest. 2020;130(5):2673-2688. |
2020-04 |
News article
|
|
Coles C.H., McMurran C. et al.
|
T Cell Receptor interactions with Human Leukocyte Antigen govern indirect peptide selectivity for the cancer testis antigen MAGE-A4. J Biol Chem. 2020;295(33):11486-11494. |
2020-08 |
News article
|
|
Crean R.M. et al.
|
Molecular rules underpinning enhanced affinity binding of T cell receptors engineered for immunotherapy. Mol Ther Oncolytics. 2020;18:443-456. |
2020-09 |
News article
|
|
Fergusson J.R. et al.
|
Immune-mobilising monoclonal T cell receptors mediate specific and rapid elimination of Hepatitis B-infected cells. Hepatology. 2020 Nov;72(5):1528-1540. doi: 10.1002/hep.31503. |
2020-11 |
News article
|
|
Middleton M.R. et al.
|
Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated anti-tumor immune responses in patients with metastatic melanoma. Clin Can Res. 2020 Aug 18. doi: 10.1158/1078-0432.CCR-20-1247. |
2020-11 |
News article
|
|
Robinson R.A., McMurran C. et al.
|
Engineering soluble T-cell receptors for therapy. FEBS Journal 2021 Feb 23. doi: 10.1111/febs.15780. |
2021-02 |
News article
|
|
Orloff M.
|
Clinical Trials in Metastatic Uveal Melanoma: Immunotherapy. Ocul Oncol Pathol 2021;7:168-176. doi: 10.1159/000513336 |
2021-03 |
News article
|
|
Yang H., et al.
|
Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses. Cell Rep. 2021 May 11;35(6):109103. doi: 10.1016/j.celrep.2021.109103. |
2021-05 |
News article
|
|
Weaver E., et al.
|
The Present and Future Role of Microfluidics for Protein and Peptide-Based Therapeutics and Diagnostics. Appl. Sci. 2021, 11(9), 4109; doi: 10.3390/app11094109 |
2021-04 |
News article
|
|
Lanz A-L., et al.
|
Allosteric activation of T cell antigen receptor signaling by quaternary structure relaxation. Cell Rep. 2021 July 13;36(2):109375. doi: 10.1016/j.celrep.2021.109375 |
2021-07 |
News article
|
|
McDaid W.J. et al.
|
Enhanced target-specific delivery of docetaxel-loaded nanoparticles using engineered T cell receptors. Nanoscale. 13(35):15010-15020. doi: 10.1039/d1nr04001d. |
2021-08 |
News article
|
|
Curnock, A., et al.
|
Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors. JCI Insight. 2021 Sep 7;152468. doi: 10.1172/jci.insight.152468. |
2021-09 |
News article
|
|
Nathan P., et al.
|
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021 Sep 23;385(13):1196-1206. doi: 10.1056/NEJMoa2103485. |
2021-08 |
News article
|
|
Weaver E., et al.
|
Microfluidic-Mediated self-assembly of Phospholipids for the delivery of Biologic Molecules. Int J Pharm 2021 Dec 7;611:121347. doi: 10.1016/j.ijpharm.2021.121347. |
2022-01 |
News article
|
|
Hassel JC, Stanhope S, Greenshields-Watson A, et al.
|
Tebentafusp induces a T cell driven rash in melanocyte-bearing skin as an adverse event consistent with the mechanism of action. J Invest Dermatol. Published online July 15, 2024. |
2024-07 |
News article
|
|
Szoke-Kovacs, R. et al.
|
Insights into the CD1 lipidome. Front. Immunol. 2024 Aug 22;15:1462209. doi: 10.3389/fimmu.2024.1462209 |
2024-08 |
News article
|
|
Brunnberg, J. et al.
|
Dual role of the peptide-loading complex as proofreader and limiter of MHC-I presentation. Proc Natl Acad Sci USA 121 (22) e2321600121 |
2024-05 |
View
|
|
Karuppiah, V. et al.
|
Broadening specificity of T-cell receptors for HLA-A*03:01/A*11:01 alloselectivity. Scientific Reports |
2024-11 |
View
|
|
Powell, T. et al.
|
GingisREX®: A complementary enzyme for the detection of bacterial proteins Journal of the American Society for Mass Spectrometry |
2024-12 |
PubMed
|
|
Murugesan, G et al.
|
Viral sequence determines HLA-E-restricted T cell recognition of hepatitis B surface antigen. Nat Comms |
2024-11 |
View
|
|
Ribeiro A, et al.
|
High-affinity T cell receptor ImmTAC® bispecific efficiently redirects T cells to 1 kill tumor cells expressing the cancer testis antigen PRAME. Immunotherapy Advances |
2024-11 |
PubMed
|
|
de Wet, B, et al.
|
Characterization of human CD8αβ interaction with classical and unconventional MHC molecules. Eur J Immunol |
2024-12 |
PubMed
|
|
Ribeiro A, et al.
|
High-affinity T cell receptor ImmTAC® bispecific efficiently redirects T cells to 1 kill tumor cells expressing the cancer testis antigen PRAME. Immunotherapy Advances |
2024-11 |
PubMed
|
|
de Wet, B, et al.
|
Characterization of human CD8αβ interaction with classical and unconventional MHC molecules. Eur J Immunol |
2024-12 |
PubMed
|
|
Güç E, Treveil A, Leach E, et al.
|
Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer |
2025-03 |
View
|
|
Sakamoto-Rablah E, Bye J, Modak A, et al.
|
Synthetic T-Cell Receptor-like Protein Behaves as a Janus Particle in Solution |
2025-01 |
PubMed
|
|
Lopez JS, Milhem M, Butler MO, et al.
|
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies |
2025-02 |
PubMed
|
|
Quast NP, Abanades B, Guloglu B, et al.
|
T-cell receptor structures and predictive models reveal comparable alpha and beta chain structural diversity despite differing genetic complexity |
2025-03 |
PubMed
|
|
Suckling RJ, Pamukcu C, Simmons RA, et al.
|
Molecular basis underpinning MR1 allomorph recognition by an MR1-restricted T cell receptor |
2025-03 |
View
|
|
Beylergil V, Collins L, Schwartz LH, et al.
|
Radiomic markers associated with clinical benefit in patients with radiographic progression of advanced uveal melanoma on tebentafusp |
2025-03 |
View
|
|
Powell T, Karuppiah V, Shaikh SA, et al.
|
Determining T-cell Receptor Binding Orientation and Peptide-HLA Interactions Using Cross-Linking Mass Spectrometry |
2025-03 |
View
|
|
Sacco, JJ & Kirk P, et al.
|
Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific |
2025-04 |
View
|
|
Powell T, Ebner M, Creese A
|
Tandem mass spectrometry fragmentation patterns of sulfo-SDA cross-linked peptides. European Journal of Mass Spectrometry. 2025;0(0). |
2025-05 |
View
|
|
D.V. Bharathi, et al.
|
Online AEX-MS Analysis of Biotherapeutic Charge Variants Using a BioAccord™ LC-MS System. Waters Application Note, November 2023 |
2023-11 |
View
|
|
Staeger, R. et al.
|
Staeger R, Tastanova A, Ghosh A, et al. Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patients. J Clin Invest. 2025;135(12):e181464. Published 2025 Apr 29. doi:10.1172/JCI181464 |
2025-04 |
View
|
|
Szoke-Kovacs R et al.
|
Szoke-Kovacs R, Khakoo S, Rangel VL, et al. A CD1c lipid agnostic T cell receptor bispecific engager redirects T cells against CD1c+ cells. Front Immunol. 2025;16:1614610. Published 2025 Jul 24. doi:10.3389/fimmu.2025.1614610 |
2025-07 |
View
|
|
Pope HC, et al.
|
Pope HC, Chiodetti AL, Newey A, et al. Cell-targeted PD-1 agonists are potent NK-cell inhibitors. Front Immunol. 2025;16:1640509. Published 2025 Aug 22. doi:10.3389/fimmu.2025.1640509 |
2025-08 |
View
|
|
Powell T, Ebner M and Creese A.
|
Powell et al. Reliable Identification of Intra- and Inter-Molecular Cross-Links in T Cell Receptor Complexes (2025). Application note. Protein Metrics |
2025-10 |
View
|
|
Sato T et al.
|
Sato T, Butler MO, Piperno-Neumann S, et al. Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 patients. Clin Cancer Res. Published online September 12, 2025. doi:10.1158/1078-0432.CCR-25-1513 |
2025-10 |
View
|
|
Watkins C et al.
|
Watkins, C., del Carpio, L. & Piulats, J.M. Comment on: “Tebentafusp Versus Nivolumab Plus Ipilimumab for Metastatic Uveal Melanoma: An E‑Value Sensitivity Analysis Assessing Effect of Unmeasured Confounders on Observational Associations”. Clin Drug Investig (2025). https://doi.org/10.1007/s40261-025-01468-1 |
2025-10 |
View
|